{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:10:14Z","timestamp":1790536214189,"version":"4.1.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:00:00Z","timestamp":1629763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Patients with the monogenic immune dysregulatory syndrome autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), which is caused by loss-of-function mutations in the autoimmune regulator (<jats:italic>AIRE<\/jats:italic>) gene, uniformly carry neutralizing autoantibodies directed against type-I interferons (IFNs) and many develop autoimmune pneumonitis, both of which place them at high risk for life-threatening COVID-19 pneumonia. Bamlanivimab and etesevimab are monoclonal antibodies (mAbs) that target the SARS-CoV-2 spike protein and block entry of SARS-CoV-2 in host cells. The use of bamlanivimab and etesevimab early during infection was associated with reduced COVID-19\u2013associated hospitalization and death in patients at high risk for progressing to severe disease, which led the US Food and Drug Administration to issue an emergency use authorization for their administration in non-hypoxemic, non-hospitalized high-risk patients. However, the safety and efficacy of these mAbs has not been evaluated in APECED patients. We enrolled two siblings with APECED on an IRB-approved protocol (NCT01386437) and admitted them prophylactically at the NIH Clinical Center for evaluation of mild-to-moderate COVID-19. We assessed the safety and clinical effects of early treatment with bamlanivimab and etesevimab. The administration of bamlanivimab and etesevimab was well tolerated and was associated with amelioration of COVID-19 symptoms and prevention of invasive ventilatory support, admission to the intensive care, and death in both patients without affecting the production of antibodies to the nucleocapsid protein of SARS-CoV-2. If given early in the course of COVID-19 infection, bamlanivimab and etesevimab may be beneficial in APECED and other high-risk patients with neutralizing autoantibodies directed against type-I IFNs.<\/jats:p>","DOI":"10.3389\/fimmu.2021.720205","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T12:37:53Z","timestamp":1629808673000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["SARS-CoV-2 Spike Protein-Directed Monoclonal Antibodies May Ameliorate COVID-19 Complications in APECED Patients"],"prefix":"10.3389","volume":"12","author":[{"given":"Elise M. N.","family":"Ferr\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica M.","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Ochoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey B.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elana R.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D.","family":"Burbelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Stoddard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakuntala","family":"Rampertaap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"DiMaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna R. E.","family":"Bergerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio D.","family":"Rosenzweig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi D.","family":"Notarangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michail S.","family":"Lionakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"eabd4570","DOI":"10.1126\/science.abd4570","article-title":"Inborn Errors of Type I IFN Immunity in Patients With Life-Threatening COVID-19","volume":"370","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.13719","article-title":"Presence of Genetic Variants Among Young Men With Severe COVID-19","volume":"324","author":"Van Der Made","year":"2020","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"eabd458","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies Against Type I Ifns in Patients With Life-Threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-021-01036-0","article-title":"Neutralizing Autoantibodies to Type I Ifns in >10% of Patients With Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain","volume":"41","author":"Troya","year":"2021","journal-title":"J Clin Immunol"},{"key":"B5","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abh2624","article-title":"Type I Interferon Autoantibodies Are Associated with Systemic Immune Alterations In Patients with COVID-19","author":"Van Der Wijst M","year":"2021","journal-title":"Sci Transl Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/imcb.12495","article-title":"Neutralizing Type-I Interferon Autoantibodies Are Associated With Delayed Viral Clearance and Intensive Care Unit Admission in Patients With COVID-19","author":"Abers","year":"2021","journal-title":"Immunol Cell Biol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.medj.2020.12.001","article-title":"Life-Threatening Covid-19: Defective Interferons Unleash Excessive Inflammation","volume":"1","author":"Zhang","year":"2020","journal-title":"Medicine (New York)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.1371\/journal.pmed.0030289","article-title":"Anti-Interferon Autoantibodies in Autoimmune Polyendocrinopathy Syndrome Type 1","volume":"3","author":"Meager","year":"2006","journal-title":"PLoS Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1146\/annurev.immunol.25.022106.141532","article-title":"Aire","volume":"27","author":"Mathis","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.9","article-title":"AIRE Expands: New Roles in Immune Tolerance and Beyond","volume":"16","author":"Anderson","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12714","article-title":"Lessons From Primary Immunodeficiencies: Autoimmune Regulator and Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy","volume":"287","author":"Constantine","year":"2019","journal-title":"Immunol Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2017.10.003","article-title":"Insights Into Immune Tolerance From AIRE Deficiency","volume":"49","author":"Proekt","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e20210554","DOI":"10.1084\/jem.20210554","article-title":"Preexisting Autoantibodies to Type I Ifns Underlie Critical COVID-19 Pneumonia in Patients With APS-1","volume":"218","author":"Bastard","year":"2021","journal-title":"J Exp Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01323-4","article-title":"A COVID-19 Pneumonia Case Report of Autoimmune Polyendocrine Syndrome Type 1 in Lombardy, Italy: Letter to the Editor","volume":"43","author":"Beccuti","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-021-00994-9","article-title":"Plasma Exchange to Rescue Patients With Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia","volume":"41","author":"De Prost","year":"2021","journal-title":"J Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-021-01023-5","article-title":"Interferon-Beta Therapy in a Patient With Incontinentia Pigmenti and Autoantibodies Against Type I Ifns Infected With SARS-CoV-2","volume":"41","author":"Bastard","year":"2021","journal-title":"J Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.03.034","article-title":"Severe COVID-19 in an APS1 Patient With Interferon Autoantibodies Treated With Plasmapheresis","volume":"148","author":"Lemarquis","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1101\/2020.09.30.318972","article-title":"LY-Cov555, A Rapidly Isolated Potent Neutralizing Antibody, Provides Protection in a Non-Human Primate Model of SARS-CoV-2 Infection","author":"Jones","year":"2020","journal-title":"bioRxiv"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2381-y","article-title":"A Human Neutralizing Antibody Targets the Receptor-Binding Site of SARS-CoV-2","volume":"584","author":"Shi","year":"2020","journal-title":"Nature"},{"key":"B20","unstructured":"Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Monoclonal Antibody Bamlanivimab [Online]2021"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0202","article-title":"Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial","volume":"325","author":"Gottlieb","year":"2021","journal-title":"JAMA"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102685","article-title":"Bamlanivimab Plus Etesevimab in Mild or Moderate Covid-19","author":"Dougan","year":"2021","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e88782","DOI":"10.1172\/jci.insight.88782","article-title":"Redefined Clinical Features and Diagnostic Criteria in Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy","volume":"1","author":"Ferre","year":"2016","journal-title":"JCI Insight"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa273","article-title":"Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019","volume":"222","author":"Burbelo","year":"2020","journal-title":"J Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"eaav5597","DOI":"10.1126\/scitranslmed.aav5597","article-title":"Lymphocyte-Driven Regional Immunopathology in Pneumonitis Caused by Impaired Central Immune Tolerance","volume":"11","author":"Ferre","year":"2019","journal-title":"Sci Transl Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.609253","article-title":"An Aireless Breath: Pneumonitis Caused by Impaired Central Immune Tolerance","volume":"11","author":"Ferre","year":"2020","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in Hospitalized Patients With Covid-19","volume":"384","author":"Group","year":"2021","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.09.010","article-title":"Coronavirus Disease 2019 in Patients With Inborn Errors of Immunity: An International Study","volume":"147","author":"Meyts","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e150867","DOI":"10.1172\/JCI150867","article-title":"Mild COVID-19 Despite Autoantibodies Against Type I Ifns in Autoimmune Polyendocrine Syndrome Type 1","volume":"131","author":"Meisel","year":"2021","journal-title":"J Clin Invest"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, A Neutralizing Antibody Cocktail, in Outpatients With Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.720205\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T23:33:24Z","timestamp":1673134404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.720205\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,24]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2021.720205"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.720205","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,24]]},"article-number":"720205"}}